Citigroup Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $102

Benzinga · 11/26/2025 19:17
Citigroup analyst Samantha Semenkow initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $102.